Meiji Yasuda Asset Management Co Ltd. Makes New Investment in West Pharmaceutical Services, Inc. $WST

Meiji Yasuda Asset Management Co Ltd. purchased a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 12,910 shares of the medical instruments supplier’s stock, valued at approximately $4,635,000.

Other institutional investors also recently modified their holdings of the company. Bank of Nova Scotia increased its holdings in shares of West Pharmaceutical Services by 337.8% during the 1st quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock worth $16,373,000 after acquiring an additional 50,402 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in West Pharmaceutical Services by 23.3% during the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock valued at $40,425,000 after purchasing an additional 27,745 shares during the last quarter. Renaissance Technologies LLC boosted its position in West Pharmaceutical Services by 100.2% during the first quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock worth $52,549,000 after purchasing an additional 104,924 shares during the period. Conestoga Capital Advisors LLC boosted its position in West Pharmaceutical Services by 6.7% during the first quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock worth $32,826,000 after purchasing an additional 8,179 shares during the period. Finally, Comerica Bank increased its holdings in shares of West Pharmaceutical Services by 31.8% in the fourth quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier’s stock valued at $15,599,000 after purchasing an additional 13,680 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Stephens reaffirmed an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Morgan Stanley raised their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Citigroup boosted their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Evercore reaffirmed an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Price Performance

NYSE:WST opened at $352.94 on Monday. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The firm has a market cap of $24.84 billion, a price-to-earnings ratio of 45.19, a P/E/G ratio of 2.47 and a beta of 1.15. The firm’s 50-day simple moving average is $348.61 and its 200 day simple moving average is $300.19. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same quarter in the previous year, the firm posted $1.84 EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, sell-side analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.